Despite both being keratinocyte-derived skin cancers, basal cell carcinoma (BCC) responds much less robustly to immunotherapy than cutaneous squamous cell carcinoma (CSCC). The pathologic complete response rate to perioperative PD-1 inhibition in BCC is only 23%, less than half the 51% seen in CSCC, highlighting their distinct immunobiology.

Medical progress isn't just about new therapies; it's also about de-escalation, such as reducing the number of radiotherapy sessions. This type of innovation significantly improves a patient's quality of life by minimizing the exhaustive and disruptive time spent in treatment, a benefit patients value highly.

In survivors over 50, an increased risk of secondary cancers is specifically associated with prior radiation treatment received 30+ years ago. The study found no similar association with chemotherapy exposures, highlighting the exceptionally long-term and distinct risks of radiation. This underscores the importance of modern efforts to reduce or eliminate its use.

Experts express strong confidence in the effectiveness of radiation therapy for epithelioid sarcomas, noting the tumors are very sensitive to it. In difficult locally advanced cases, radiation is a key modality for gaining disease control and managing pain, with growing interest in combining it with immunotherapy to enhance its effects.

Contrary to the common assumption that metastatic disease is the primary cause of cancer-related death, a large international study on CSCC found that two-thirds of patients died from local-regional uncontrolled progression. This highlights the critical importance of effective local control strategies.

Experts argue that radiation therapy is often wrongly perceived as a salvage or adjuvant option. For many patients with early-stage basal or squamous cell carcinomas, it offers local control rates over 95%, comparable to surgery, and should be presented as a primary alternative, especially when cosmetic outcomes are a priority.

Patients receiving systemic immunotherapy for advanced skin cancer are still at high risk for developing new, low-risk primary skin cancers. Medical oncologists should not act as default dermatologists; ongoing co-management is crucial to identify and treat these new lesions while the patient is on systemic therapy.

Unlike photon radiation ("flashlights") used for deep tumors, electron radiation ("tennis balls") has mass and stops near the surface. This makes it an ideal tool for treating many skin cancers, as it minimizes radiation dose and toxicity to underlying healthy tissues and organs.

The high efficacy of checkpoint inhibitors in cutaneous squamous cell carcinoma is enabling a "de-escalation" strategy. Upfront systemic therapy can be so effective that it eliminates the need for subsequent morbid local treatments like extensive surgery or radiation, a major benefit for elderly patients.